Recent discussions on X about AbbVie (ABBV) have centered around the company’s strong performance in the pharmaceutical sector, particularly following reports of a significant stock price increase and consistent sales growth. Many users have highlighted the stock’s recent surge to over $190 per share, with some pointing to quarterly sales growth figures as a key driver of interest. There’s also buzz about AbbVie’s robust portfolio of drugs and its status as a dividend standout, sparking conversations about long-term potential.
Additionally, posts on X have noted positive momentum in the broader pharma sector, with some attributing AbbVie’s gains to favorable industry trends and competitor updates. Enthusiasm is evident as users discuss the company’s pipeline of innovative treatments and its attractive dividend yield, though a few caution about market volatility impacting future performance. The tone of these conversations reflects optimism with a hint of cautious curiosity.
Note: This discussion summary was generated from an AI condensation of post data.
AbbVie Congressional Stock Trading
Members of Congress have traded $ABBV stock 13 times in the past 6 months. Of those trades, 9 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 4 times. They made 3 purchases worth up to $45,000 on 05/22, 04/03, 04/01 and 1 sale worth up to $15,000 on 04/17.
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 3 times. They made 2 purchases worth up to $30,000 on 05/15, 02/25 and 1 sale worth up to $15,000 on 04/08.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/05, 03/17 and 0 sales.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 1 purchase worth up to $100,000 on 02/24 and 1 sale worth up to $100,000 on 04/17.
- REPRESENTATIVE JARED MOSKOWITZ purchased up to $15,000 on 04/07.
- REPRESENTATIVE DWIGHT EVANS sold up to $15,000 on 04/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AbbVie Insider Trading Activity
AbbVie insiders have traded $ABBV stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- TIMOTHY J. RICHMOND (EVP, CHIEF HR OFFICER) has made 0 purchases and 6 sales selling 29,917 shares for an estimated $6,070,036.
- KEVIN K BUCKBEE (SVP, CONTROLLER) has made 0 purchases and 2 sales selling 18,944 shares for an estimated $3,853,372.
- SCOTT T REENTS (EVP, CHIEF FINANCIAL OFFICER) sold 17,644 shares for an estimated $3,746,526
- PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 2 sales selling 5,778 shares for an estimated $1,143,452.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AbbVie Hedge Fund Activity
We have seen 1,694 institutional investors add shares of AbbVie stock to their portfolio, and 1,686 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GAMMA INVESTING LLC removed 10,182,211 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $1,890,022,005
- CAPITAL INTERNATIONAL INVESTORS removed 7,996,758 shares (-28.0%) from their portfolio in Q1 2025, for an estimated $1,675,480,736
- FMR LLC added 5,539,207 shares (+30.6%) to their portfolio in Q1 2025, for an estimated $1,160,574,650
- BLACKROCK, INC. added 3,842,577 shares (+2.7%) to their portfolio in Q1 2025, for an estimated $805,096,733
- ASSENAGON ASSET MANAGEMENT S.A. added 3,666,521 shares (+550.9%) to their portfolio in Q2 2025, for an estimated $680,579,628
- GOLDMAN SACHS GROUP INC added 3,351,687 shares (+29.7%) to their portfolio in Q1 2025, for an estimated $702,245,460
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC added 3,134,454 shares (+inf%) to their portfolio in Q2 2025, for an estimated $581,817,351
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AbbVie Government Contracts
We have seen $512,569 of award payments to $ABBV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- IMPLANTS: $36,934
- IMPLANT: $35,788
- 4567253744!NATRELLE TE SMOOTH 133S-SV-13-T: $33,629
- IMPLANTS: $29,604
- PROSTHETICS:SURGICAL IMPLANTS BREAST RECONSTRUCTION: $29,513
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AbbVie Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 04/29/2025
- Morgan Stanley issued a "Overweight" rating on 04/28/2025
- Evercore ISI Group issued a "Outperform" rating on 04/28/2025
- Raymond James issued a "Outperform" rating on 04/28/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/22/2025
- Wells Fargo issued a "Overweight" rating on 03/05/2025
- BMO Capital issued a "Outperform" rating on 02/03/2025
To track analyst ratings and price targets for AbbVie, check out Quiver Quantitative's $ABBV forecast page.
AbbVie Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 12 analysts offer price targets for $ABBV in the last 6 months, with a median target of $215.5.
Here are some recent targets:
- Geoff Meacham from Citigroup set a target price of $205.0 on 05/14/2025
- Vamil Divan from Guggenheim set a target price of $216.0 on 04/29/2025
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $205.0 on 04/28/2025
- Gary Nachman from Raymond James set a target price of $227.0 on 04/28/2025
- Terence Flynn from Morgan Stanley set a target price of $250.0 on 04/28/2025
- Carter Gould from Cantor Fitzgerald set a target price of $210.0 on 04/22/2025
- Asad Haider from Goldman Sachs set a target price of $194.0 on 04/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
